The collaboration between Oncology Metrics’s sample procurement network Cure Pace and Cureline is expected to improve the access of industrial and academic researchers to high-quality biospecimens.
Olga Potapova, founder and CEO of Cureline, said that she views the collaboration as a unique opportunity to provide to academia and the industry cancer biospecimens collected from diverse ethnic background populations through Cureline’s clinical network in eastern Europe and Asia and through the Oncology Metrics’s clinical network in the US.
Commenting on the collaboration, Warren Dodge, president and CEO of Oncology Metrics, said: “By leveraging the scientific expertise and access to tissue and our domestic access to serum and fresh whole blood, we become a much better resource for the scientists looking to advance the treatment of cancer.”